Athira Pharma raises $85M Series B to push NDX-1017 toward FDA approval for Alzheimer’s, Parkinson’s and ALS

Seattle biotech Athira Pharma raised $85 million in a Series B round to advance NDX-1017, a regenerative therapy aimed at halting or reversing nerve damage in Alzheimer’s, Parkinson’s and ALS, with preliminary trial results reported as positive and potential market availability in 2–3 years.